Exchange: NASDAQ·Updated 07:45 PM EDT
News
all
press releases
$1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth This Much Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 5 years by 4.4% on an annualized basis producing an average annual return of 15.54%. Currently, Gilead Sciences has a market capitalization ofread more...
Benzinga
More News
GILD Stock Garners Retail Attention On Trodelvy EU Approval Ahead Of August 27 HIV FDA Verdict
The European Commission on Monday authorized Trodelvy combined with Merck’s (MRK) Keytruda for certain adults with previously untreated advanced or metastatic triple-negative breast cancer.
Stocktwits
Gilead: European Commission Approves Trodelvy Plus Keytruda In PD-L1-positive Metastatic TNBC
(RTTNews) - Gilead Sciences (GILD) announced the European Commission has granted marketing authorization for Trodelvy in combination with Keytruda for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer who have not rec...
Nasdaq News: Markets
European Commission Expands Role of Gileads Trodelvy in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) for the treatment of adult patients with unresectable, locally advanced or metastatic...
Business Wire
Is Gilead's Expanding HIV Portfolio a Growth Catalyst?
Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects.
Zacks
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.
Key PointsGilead has been quite active in acquisitions this year...
Nasdaq News: Markets
Did You Lose Money Investing in iTonic Holdings Ltd.? Robbins LLP Urges Investors With Significant Losses to Contact the Firm for Information About Their Rights Against ITOC
Did You Lose Money Investing in iTonic Holdings Ltd.? Robbins LLP Urges Investors With Significant Losses to Contact the Firm for Information About Their Rights Against ITOC Did You Lose Money Investing in iTonic Holdings Ltd.? Robbins LLP Urges Investors With Significant Losses to Contact the Firm...
PR Newswire
Court rules companies can't import Gilead medications from overseas in blow to AFP health programs
A U.S. appeals court has ruled in favor of Gilead Sciences against companies known as alternative funding programs that import medicines from overseas...
CNBC: Healthcare
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.04% on an annualized basis producing an average annual return of 11.31%. Currently, Gilead Sciences has a market capitalization ofread more...
Benzinga
J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?
J&J's growth, new drug launches and pipeline strength support the stock, despite patent, MedTech and legal headwinds.
Zacks

Advertisement|Remove ads.